The Artificial Heart Market is focused on the development and deployment of implantable mechanical circulatory support systems, primarily the Total Artificial Heart ($\text{TAH}$), which are used as a bridge to transplantation (BTT) for patients with end-stage biventricular heart failure. A $\text{TAH}$ replaces both native ventricles and valves, providing hemodynamic support when a ventricular assist device ($\text{VAD}$) is inadequate.Artificial Heart Market.

The market is characterized by complex, high-cost, and life-saving technology, with ongoing development focused on improving device durability, reducing the risk of stroke ($\text{thromboembolism}$), and miniaturizing external components. Clinical Trials and Regulatory Approvals are the central determinants of market growth, as long-term $\text{TAH}$ use requires impeccable reliability and reduced dependency on external power sources. The ultimate goal is to evolve the $\text{TAH}$ from a temporary BTT solution into a viable Destination Therapy for patients ineligible for transplantation, which drives continuous engineering and clinical investment 

Related Reports